In the News
Dr. Sung discusses pancreatic cancer in The Daily News feature The Daily Check Up.
View the PDF.
American Board of Internal Medicine
MD, Albert Einstein College of Medicine
Internship, Internal Medicine
Montefiore Medical Center
Residency, Internal Medicine
Montefiore Medical Center
Montefiore Medical Center
Fellowship, Neoplastic Diseases
Mount Sinai Hospital
Dr. Sung is currently conducting clinical trials of immunotherapy in patients with advanced colorectal and breast cancers using gene transfer therapy. He is also involved in clinical trials of suicide gene therapy and differentiation therapies for colorectal cancer, and anti-angiogenesis therapy for hepatocellular carcinoma.
Dr. Sung actively participates in multi-modality treatment approaches (surgery/radiation/chemotherapy) to cancers of the liver, colon-rectum, carcinoid, pancreas, esophagus, stomach and anal cancers, and is also experienced in regional treatment modalities such as hepatic arterial chemotherapy/chemoembolization and intraperitoneal chemotherapy.
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma
The purpose of this study is to obtain information on the safety and tolerability of an experimental drug called BLU-554 when it is given to patients with Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma. Experimental means that it is not yet known if this drug helps p...
A Phase 2B, randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma
A vaccine is something that is given to boost a person's immune system to fight or protect against disease. The purpose of this study is to test whether GVAX pancreas vaccine and CRS-207, a weakened form of Listeria bacteria that has been modified to reduce the likelihood t...
A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma
The purpose of this study is to test the effectiveness (how well the drug works), safety, and rolerability of an investigational drug called nivolumab (also known as BMS-936558). In this study, nivolumab will be tested in participants with advanced liver cancer who have not...
A Multicenter, randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Levantinib (E7080) versus Sorafenib in First Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma
Lenvatinib (E7080) is a drug that is being developed for the treatment of ...
Sung MW, Yeh HC, Thung SN, Schwartz ME, Mandeli JP, Chen SH, Woo SL C. Intratumoral Adenovirus-Mediated Suicide Gene Therapy for Hepatic Metastases from Colorectal Adenocarcinoma: Results of a Phase I Clinical Trial. Mol Ther 2001; 4: 182.
Sung MW, Chen SH, Thung SN, Zhang DY, Huang TG, Mandeli JP, Woo SL C. Intratumoral Delivery of Adenovirus-Mediated Interleukin-12 Gene in Mice Bearing Metastatic Cancer in the Liver. Hum Gene Ther 2002; 13: 731.
Sung MW, Chen SH, Woo SL C. New Approaches to Gene Therapy for Cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Progress in Oncology 2002. Sudbury, Massachusetts, Jones & Bartlett; 2002. pp36-53.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Sung did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.